Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Add To Watchlist

Recent & Breaking News (NDAQ:DCTH)

Delcath Issues Letter to Stockholders

GlobeNewswire April 27, 2017

Delcath Announces 2016 Financial Results

GlobeNewswire March 29, 2017

Delcath Announces Special Protocol Assessment Agreement With FDA for Pivotal Trial With Melphalan/HDS in Intrahepatic Cholangiocarcinoma

GlobeNewswire March 27, 2017

Healthcare Stocks on Investors' Radar -- Delcath Systems, Palatin Technologies, AMAG Pharma, and IDEXX Laboratories

PR Newswire March 14, 2017

Delcath Systems To Present At ROTH Capital Partners 29th Annual Growth Stock Conference On March 13, 2017

GlobeNewswire March 10, 2017

Published Review Shows Delcath Investigational PHP Doubles Overall Survival Over Other Targeted Liver Therapies

GlobeNewswire February 22, 2017

Analysis From Two Institutions Shows Strong Tumor Response, Overall Survival Potential of Delcath Investigational PHP Therapy

GlobeNewswire February 21, 2017

Delcath Systems to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

Accesswire February 6, 2017

Research Reports Initiation on Healthcare Stocks -- Palatin Technologies, AMAG Pharma, IDEXX Labs, and Delcath Systems

PR Newswire February 6, 2017

Delcath Systems To Present At The NobleCon13 - Noble Capital Markets' Thirteenth Annual Investor Conference On January 31, 2017

PR Newswire January 23, 2017

New Outcomes Data Using Delcath's Melphalan/HDS To Treat Unresectable Metastatic Ocular Melanoma To The Liver Accepted For Oral Presentation At Regional Cancer Therapies Symposium

PR Newswire January 18, 2017

Delcath Announces Ongoing Patient Treatment And Data Collection In Intrahepatic Cholangiocarcinoma Study Cohort

PR Newswire January 12, 2017

12 Biggest Mid-Day Losers For Thursday

Benzinga.com December 22, 2016

Delcath Systems to Present at the 9th Annual LD Micro Main Event

Accesswire November 30, 2016

Delcath Announces Third Quarter Financial Results

PR Newswire November 11, 2016

Delcath Issues Letter to Stockholders

PR Newswire October 18, 2016

Review Of Delcath's CHEMOSAT Accepted For Publication In Advances In Therapy

PR Newswire October 17, 2016

Delcath Announces First European Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases

PR Newswire October 12, 2016

Delcath Announces New U.S. Clinical Sites For FOCUS Phase 3 Trial For Ocular Melanoma Liver Metastases

PR Newswire October 11, 2016

Delcath To Present At The Dawson James Securities Growth Stock Conference

PR Newswire October 5, 2016